Magnesium revealed to have properties of bronchodilation in chronic obstructive pulmonary disease (COPD) and asthma. A clinical benefit of nebulization with magnesium has been observed in asthma. The aim of the analysis was the therapeutic benefits comparison of using magnesium sulphate in nebulized form as an adjuvant of the normal saline solution among patients with exacerbations of COPD.

Study Design: A randomized single blind interventional study.

Place and Duration: In the Department of Medicine, Islam Medical College and Teaching Hospital Sialkot for six months duration from March 2021 to September 2021

Methods: This study involved 132 cases of acute COPD exacerbations with PEFR <300 L / min, evaluated twenty mints after initial therapy. Patients were administered salbutamol 5mg mixed with 3 ml of saline or 3 ml of isotonic magnesium sulphate three times at thirty-minute intervals using a nebulizer. At 90 minutes: Primary outcome of PEFR were measured and admission to hospital, invasive or non-invasive ventilation along with mortality were measured as 2^ndry outcomes.

Results: After nebulization with magnesium sulphate, the mean PEFR was 86.3 ± 11.9 l / min, 97.6 ± 19.1 l / min and 99.6 ± 15.2 l / min and 79.17 ± 14.11 l / min, 90.17 ± 18.27 l / min, and 93.17. ± 20.63 L. Statistically significant differences were found in the normal saline group at thirty, sixty and ninety minutes, correspondingly. In the magnesium group, 91.9% were admitted to the ward, 8.1% to the intensive care unit, 81.7% to the ward, and 18.3% to the salt group to the intensive care unit. The differences in ventilation and mortality were negligible.

Conclusions: In the context of AECOPD, nebulized magnesium sulphate in combination with salbutamol has a therapeutic advantage over PEFR, but has no effect on hospitalization, the need for mortality and non-invasive or invasive ventilation.

Keywords: Peak expiratory flow, magnesium sulphate and chronic obstructive pulmonary disease.